IL17A and asthma: Preclinical studies suggest that IL-17-mediated expression of cytokines and chemokines in structural cells contributes to neutrophilic inflammation, airway remodeling, loss of lung function and lung damage in COPD, CF, and asthma, and tumor proliferation and resistance to immunotherapy.